Bax/Bcl-2 Expression in Pediatric Acute Lymphoblastic Leukemia
Researchers sought to determine the impact of Bax and Bcl-2 expression in pediatric patients with acute lymphoblastic leukemia after completing induction chemotherapy.
Acute Lymphoblastic Leukemia
Combo Produces High Response Rate in Older Adults With Ph-Negative B-ALL
The combination produced an overall response rate of 99%, and the 5-year remission rate was 76%.
Blinatumomab Linked to Higher Costs, Hospitalizations for R/R ALL
The mean total cost of care was $65,437 for blinatumomab, $55,995 for inotuzumab, and $17,520 for other agents.
Researchers Identify RAD21 Variants in Pediatric Lymphoblastic Leukemia or Lymphoma
Researchers sought to determine the relevance of the RAD21 gene in pediatric lymphoblastic leukemia or lymphoma.
Long-Term Mortality Rates Elevated for Adolescent, Young Adult Leukemia Survivors
Survival for adolescent and young adult leukemia survivors remained below general population at up to 30 years of follow-up.
Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant
There was no significant difference in transplant-related mortality or overall survival.
Real-World Outcomes of Tisagenlecleucel in Patients Younger Than 3 Years With Acute Lymphoblastic Leukemia
Researchers sought to determine whether tisagenlecleucel is safe and effective in patients younger than 3 years old with relapsed/refractory ALL.
Serum Asparaginase Activity Level Measurement Recommended in Infants With Acute Lymphoblastic Leukemia
Researchers sought to determine whether monitoring SAA levels would be a helpful strategy for determining therapy efficacy in infants with ALL.
Consensus Recommendations Published for Chronic Graft Vs Host Disease Management of Pediatric Patients With ALL
Researchers sought to improve the understanding of cGVHD in pediatric patients with ALL after they receive allo-HSCT.
Adding Eprenetapopt to Maintenance Azacitidine Promising After HCT in MDS/AML
Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.
- Loading...
Loading...
Next post in Tandem Meetings 2022
Loading... 
Loading...